ABSTRACT Background: Factors that affect resting energy expenditure or basal energy expenditure (BEE) in patients with type 2 diabetes under standard treatment have not been evaluated in detail. Objective: We determined the clinical factors that affected BEE in addition to body composition in patients with type 2 diabetes under standard treatment. Design: BEE was measured by using indirect calorimetry under a strict basal condition in 58 Japanese patients with type 2 diabetes after .7 d as inpatients under management of diabetes with medical nutrition therapy and medications. Insulin secretion was measured with a glucagon test. Stepwise regression was applied to explore determinants of BEE. Results: In the stepwise estimation, insulin secretion (P = 0.015), insulin therapy (P = 0.012), and pulse rate (P = 0.011) were selected in addition to fat-free mass (FFM) (P , 0.001) and fat mass (P = 0.006) as significant independent determinants of BEE. Standardized partial regression coefficients of the additional 3 factors were 20.16, 20.15, and 0.15, respectively, whereas those for FFM and fat mass were 0.82 and 0.19, respectively. The additional 3 factors explained another 3.9% of the variability of BEE, and the adjusted coefficient of determination was 83.4%. Age, sex, other medications, and parameters of glycemic control were not significant determinants beyond the combined contribution of body composition, endogenous and exogenous insulin, and pulse rate. Conclusion: Endogenous insulin secretion and exogenous insulin administered in treatment have significant independent effects in the lowering of BEE in patients with diabetes under standard management with medical nutrition therapy and medications.
INTRODUCTION

MNT
4 is the basis and starting point of treatment of all patients with diabetes, and the failure of MNT alone may predict the inability to attain optimal glycemic control. In addition, in obese patients with diabetes, MNT aims at weight control to improve insulin resistance and avoid obesity-related health problems. Therefore, estimation of the daily energy expenditure of patients is necessary for individualized diabetic meal plans. For example, MNT for obese patients provides a diet of 500-1000 kcal less energy than the estimated energy expenditure (1) . REE or BEE is defined as the minimal amount of energy expended to maintain metabolic activities of cells, tissues, and organs and represents a large component of daily energy expenditure. REE or BEE is used to estimate total energy expenditure as a multiple of REE or BEE according to daily activity.
In healthy subjects, 65-90% of the interindividual variation in REE is explained by FFM or high-metabolic-rate organ mass (2, 3) . In patients with diabetes, FFM is also assumed to be a main factor that affects REE and BEE. The influence of the diabetic condition on energy expenditure has also been examined. After adjustment for FFM, REE and BEE in patients with diabetes were shown to be greater than those in healthy control (4, 5) . In contrast, no difference was reported in FFM-adjusted REE between mildly hyperglycemic patients and control subjects (6) . In addition, a treatment-induced reduction of REE has been reported in type 1 and type 2 diabetes (7, 8) . However, the factors that affect REE or BEE in patients with diabetes under standard treatment, which are the more important in clinical practice, have not been precisely evaluated.
In most studies that evaluated energy expenditure, REE has been measured rather than BEE. However, resting conditions are defined less rigorously than are basal conditions, and REE can include components that involve physical or psychological stress and variations in ambient and body temperature (9) (10) (11) . BEE is measured early in the morning before the subject has engaged in any physical activity and !10 h after ingestion of any food, drink, or nicotine and remains remarkably constant on a daily basis (9, 11) . We applied the measurement of BEE under such strict basal conditions to minimize the interindividual variation derived from methodologic or external unknown factors.
In the current study, clinical factors that might affect BEE in patients with diabetes under standard treatment were evaluated.
SUBJECTS AND METHODS
Subjects
Japanese patients with type 2 diabetes who were admitted to the Department of Diabetes and Clinical Nutrition, Kyoto University Hospital, Kyoto, Japan, for diabetes self-management education during the period of December 2007 through September 2009 were recruited. The study protocol was approved by the ethics committee of Kyoto University. Written informed consent was obtained from all participants.
During admission, which averaged ;18 d, participants took MNT with or without medications, including oral hypoglycemic agents and insulin, according to the treatment guide for diabetes of the Japan Diabetes Society (12) . The physical activity of subjects was not restricted, but participants did not engage in intensive exercise. Participants were screened by a medical history, physical examination, and laboratory examination to ensure the absence of hepatic, renal (including macroalbuminurea), pulmonary, thyroid, and cardiac dysfunction, inflammation, and malignant tumors. Participants who took steroids or b-blockers and subjects who had physical disabilities were excluded.
Energy expenditure
BEE was measured in the morning .7 d after admission under glycemic control with MNT (29.0 6 2.6 kcal/kg of standard body weight/d that consisted of 52% carbohydrate, 20% protein, and 28% fat in energy-intake percentages) and with without prescribed medications. Standard body weight (in kg) was calculated by multiplying 22 (kg/m 2 ) by square of height (in m). Premenopausal women were studied during their follicular phase within 7 d after the last day of menstruation.
Whole-body oxygen consumption and carbon dioxide production were measured for .10 min with indirect calorimetry (AE300S; Minato Medical Science) by one investigator at the bedside of each participant under the strict condition of the methods described previously (9, 10, 13) . Briefly, afebrile patients in a postabsorptive state after an overnight fast (14 h) with ,10 mmol capillary PG/L before the measurement remained in a supine position after waking on the bed in the ward without smoking or taking caffeine, and measurements were performed at room temperature between 22°C and 27°C. After discarding the initial 5 min of data, we adopted 5 consecutive minutes of data from the rest in accord with the steady state definition (10) during which the CV for oxygen consumption and carbon dioxide production was achieved at 10% and applied them to the Weir formula together with 24-h urinary urea nitrogen (14) .
Body composition
Height was measured on the day of admission, and body weight was measured immediately after measurement of BEE. FFM and fat mass were measured with a dual energy X-ray absorptiometry scanner (Discovery; Hologic) within 3 d before or after the measurement of BEE.
Clinical and metabolic factors
The duration of diabetes was determined from medical records, medical histories, and previous clinical data according to the criteria for the diagnosis of diabetes proposed by the American Diabetes Association (15 which considers the relational expression of Hb A 1c (Japan Diabetes Society) (percentage) measured by using the previous Japanese standard substance and measurement methods and Hb A 1c (National Glycohemoglobin Standardization Program) (16) . Thyroid stimulating hormone was measured by using electrochemiluminescence immunoassay (Elecsys Anti-Tg; Roche Diagnostics GmbH) to confirm the absence of thyroid dysfunction. Capillary glucose before each meal was measured with a glucose meter (One Touch Ultra; Johnson & Johnson) and expressed as capillary PG. As a variable of glycemic control, the mean preprandial PG for 3 consecutive days before the measurement of BEE and FPG just before the measurement of BEE was used. The mean pulse rate was calculated from the records of checkups by nurses on 3 consecutive days including the day of BEE measurement.
Insulin secretion
b cell function was evaluated after an overnight fast by measuring CPR6# (17) because the test is valid in patients who take insulin therapy. The serum C-peptide immunoreactivity was measured by using an immunoenzymometric assay (ST AIA-PACK C-peptide; Toso). On the morning of the glucagon test, participants took their medication after the test.
Statistical analysis
Descriptive data were expressed as means 6 SDs. Information of medications, including insulin, sulfonylurea, and metformin, was coded as use = 1 and nonuse = 0. Sex was coded as male = 1 and female = 0. The Mann-Whitney U and Fisher's exact tests were performed to identify differences in the characteristics of men and women. The interrelation between BEE and clinical factors was investigated by means of Kendall's rank correlation coefficients. Clinical factors include body composition (FFM and fat mass), FPG, mean preprandial PG, A 1c , insulin secretion, mean pulse rate, dietary energy, and medications (ie, insulin, sulfonylurea, and metformin). A multiple linear regression analysis was performed to evaluate the contribution of each determinant to BEE. Variables were selected by stepwise estimation from age, sex, and the clinical factors previously described. When P was ,0.05 and !0.15, the variable was added and removed, respectively. Data were analyzed by use of Stata 11.0 software (StataCorp). Statistical significance was set at P , 0.05 (2-tailed).
RESULTS
Participant characteristics and results of measurement are shown in Table 1 . BMI (in kg/m 2 ), CPR6#, FPG, PPPG, A 1c , pulse rate, duration of diabetes, and treatment did not differ significantly between men and women, whereas body weight, FFM, and BEE were significantly higher in men, and age was higher in women.
Significant positive correlations were observed between BEE and FFM (r = 0.72) and dietary energy (r = 0.33), but dietary energy also had a significant positive correlation with FFM (r = 0.37) and a significant negative correlation with fat mass (r = 20.38) ( Table 2) . Fat mass had a significant negative correlation with mean preprandial PG (r = 20.30) and a significant positive correlation with insulin secretion (CPR6#) (r = 0.43) 
1 A 1c , glycohemoglobin; BEE, basal energy expenditure; CPR6#, C-peptide immunoreactivity 6 min after intravenous glucagon injection; FFM, fat-free mass; FPG, fasting plasma glucose just before the measurement of BEE; PPPG, mean preprandial plasma glucose for 3 consecutive days before the measurement of BEE; SBW, standard body weight.
2 Mann-Whitney U test revealed significant (P , 0.05) differences between men and women. 3 Mean 6 SD (all such data).
TABLE 2
Correlations between BEE and possible determinants of BEE ) ; CPR6#, C-peptide immunoreactivity 6 min after intravenous glucagon injection (ng/ mL); Diet, energy of diet (kcal/d); FFM, fat-free mass (kg); FM, fat mass (kg); FPG, fasting plasma glucose just before the measurement of BEE (mg/dL); PPPG, mean preprandial plasma glucose for 3 consecutive days before the measurement of BEE (mg/dL); PR, pulse rate (beats/min). * ,y,z Kendall's correlation coefficients (n = 58): *P , 0.001, y P , 0.05, z P , 0.01. Because clinical factors were naturally correlated with each other, possible spurious correlation and suppressor variables were investigated by means of multiple regression analysis. The model that predicted BEE from body composition alone is shown in Table 3 (model 1). Another model included selected variables by stepwise estimation (model 2). Insulin secretion (CPR6#; P = 0.015), use of insulin (P = 0.012) and pulse rate (P = 0.011) were significant determinants of BEE in addition to FFM (P , 0.001) and fat mass (P = 0.006). These additional factors explained another 3.9% of the variability of BEE, and the adjusted coefficient of determination was 83.4%. Standardized coefficients of FFM, fat mass, insulin secretion (CPR6#), use of insulin, and pulse rate in model 2 were 0.82, 0.19, 20.16, 20.15, and 0.15, respectively. Variance inflation factors of variables in model 2 were all ,1.5. Other plausible determinants (ie, FPG, mean preprandial PG, A 1c , dietary energy, use of sulfonylurea, use of metformin, age, and sex) were not selected as significant contributors by stepwise estimation. The effect of insulin secretion (CPR6#) in BEE adjusted for FFM, fat mass, use of insulin, and pulse rate is illustrated in Figure 1 .
DISCUSSION
In the current study, endogenous insulin secretion and exogenous insulin administered in treatment were both significant independent variables that predicted BEE in Japanese patients with type 2 diabetes under MNT and medications. In addition, both factors were negatively correlated with BEE. The current results suggested that the effect of insulin, regardless of the endogenous or exogenous source, had a significant negative impact on energy expenditure in patients with fair glycemic control under medical care.
In the current study, clinical factors regarding the effects of insulin predicted BEE, whereas factors regarding glycemic control did not predict BEE. The cause of these differing results is not clear, but the present results indicated that the effects of insulin affected BEE independently of glycemia. In a previous report, EGO was shown to be a significant predictor of elevated REE of patients with diabetes after adjustment for body composition, but the glucose concentration was not (18) . Although FPG was correlated with EGO, it accounted for only 21% of its variability (19) . Gluconeogenesis is an energy-consuming metabolic pathway and is thought to be a major source of increased EGO in diabetes (20) (21) (22) . Because hepatic insulin deficiency plays an important role in increased gluconeogenesis in diabetes 1 Model 1 predicted BEE only from body composition by linear regression analysis (n = 58). The final regression model (model 2) used independent variables selected from FFM, FM, age, sex, CPR6#, fasting plasma glucose, mean preprandial plasma glucose, A 1c , dietary energy, use of insulin, use of metformin, use of sulfonylurea, and pulse rate by stepwise estimation (n = 58). A 1c , glycohemoglobin (%); BEE, basal energy expenditure (kcal/d); Coef, partial regression coefficient; CPR6#, C-peptide immunoreactivity 6 min after intravenous glucagon injection (ng/mL); FFM, fat-free mass (kg) measured by using dual energy X-ray absorptiometry; FM, fat mass (kg) measured by using dual energy X-ray absorptiometry (kg); INS, insulin; PR, pulse rate (beats/min); Std coef, standardized coefficient.
2 Use = 1; nonuse = 0.
FIGURE 1.
Relation between CPR6# and BEE after adjustment for fatfree mass, fat mass, pulse rate, and insulin use (n = 58). BEE, basal energy expenditure; CPR6#, C-peptide immunoreactivity 6 min after intravenous glucagon injection. (19) , insulin, both endogenous and exogenous, may suppress BEE by reducing gluconeogenesis.
Protein turnover is also involved in energy expenditure. Protein turnover is often elevated in diabetes and has been shown to be correlated with REE in type 2 diabetes (23, 24) . Because the treatment-induced reduction of nitrogen flux, which is an index of protein turnover, has been shown to be correlated with the C-peptide response to an oral glucose challenge (8) , protein turnover may well play a role in the alteration of energy expenditure by insulin. In addition, impairment of insulin release is often accompanied by hyperglucagonemia in fasting and postprandial states in type 2 diabetes (25) . Hyperglucagonemia is responsible for increased leucine oxidation and REE by insulin deprivation in type 1 diabetes (26) . In addition, thermogenesis, especially via b-3 adrenergic receptors, has another impact on energy expenditure (20, 27) . Considered together, these findings suggested that glucagon and catecholamine may also affect BEE in type 2 diabetes. However, we did not measure glucagon and catecholamine, which was a limitation of the current study.
Contrary to our results, the fasting insulin concentration has been reported to be positively correlated with energy expenditure (18) . In the report (18) , the positive correlation between insulin and energy expenditure was speculated to derive from the activation of the sympathetic nervous system by insulin (28) . We showed that CPR6# and insulin use were negatively correlated with BEE independently of the pulse rate, which is an indicator of the sympathetic nerve system activity, and was positively correlated with BEE independently of CPR6# and insulin use. These findings suggested that the effect of insulin on BEE may be independent of the sympathetic nerve system activity at least in patients under treatment.
The difference in insulin sensitivity between lean Japanese subjects and obese American subjects may account for the difference in association of insulin with BEE. In general, a greater attribution of impaired insulin secretion and a lesser contribution of insulin resistance to glucose intolerance were shown in Japanese patients with type 2 diabetes, whose average BMI is ;25 but which is .30 in European and American populations (29) . This difference may be attributable, in part, to the difference in BMI; in the Swedish population, the average CPR6# is lower (;2 ng/mL) in lean subjects with BMI of ;25 than it is in obese subjects (;8 ng/mL) with BMI of ;30. Thus, our findings are in accord with those in Swedish lean subjects (30) . Our previous finding of a positive correlation between BMI and CPR6# also supported this attribution of difference in insulin secretion to difference in BMI (31) .
Glycemia was shown to not be an independent determinant of BEE in this study. Although elevated BEE or REE after adjustment for body composition in patients with diabetes compared with in healthy subjects has been reported, the glucose concentration was not described (4, 5) . Another study reported a significantly greater REE in patients with high glucose values (.10 mmol/L) compared with in patients with low glucose values (,10 mmol/L) (32) . In addition, no increase in BEE was shown in patients with glycemic concentrations of ;9.5 mmol/L (6). Blood glucose concentrations of patients in the current study were improved by treatment, and FPG concentrations and mean preprandial PG concentrations were ;115 mg/dL (6.4 mmol/L) and 144 mg/dL (8.0 mmol/L) respectively. Therefore, the finding of no association between BEE and PG concentrations in the current study was not discrepant with previous reports and was in accord with the finding that REE did not significantly correlate with fasting glucose in type 2 diabetes in which the fasting glucose concentration was ;7.4 mmol/L (18) . Together, these data suggested that glycemia is not an important factor in the prediction of BEE in patients with diabetes under treatment.
Dietary energy, treatment with sulfonylurea or metformin, age, and sex were not significant variables that predicted BEE. Sex itself was not a significant determinant but affected coefficients of FFM and fat mass when added to model 2. Researchers have noted a contribution of sex to BEE in addition to FFM and fat mass, although information of menstruation at the measurement of BEE was absent (4, 5) . In the current study, BEE was measured during the follicular phase in accordance with a strict protocol for premenopausal women to avoid the influence of progesterone, which was supposed to increase energy expenditure. Another possibility is that our sample size was not large enough to show the contribution of sex to BEE. Last, with consideration of our previous finding that CPR6# was independently influenced by BMI and the duration of diabetes in type 2 diabetes (31), we performed a regression analysis by adding these 2 putative covariates to model 2, which showed the insignificance of these determinants.
In conclusion, the current study shows that endogenous and exogenous insulin both have a significant impact on lowering BEE in patients with type 2 diabetes under standard treatment with MNT and medications. Longitudinal studies are required to elucidate the impact of the increment of C-peptide concentrations by insulinotropic agents and the administration of insulin on energy expenditure and gluconeogenesis during fair glycemic control.
